Treatment Horizon for Advanced Pancreatic Cancer

If your first treatment for advanced pancreatic cancer doesn't work and you want to try slowing the disease with a second treatment, you've got options. From a new drug that's helped people live much longer to clinical trials that test out promising experimental treatments, the outlook for this disease is gradually becoming brighter. Get the facts on these developments and others, including what artificial intelligence (AI) is capable of today and whether it has the potential to unlock future breakthroughs in the treatment and diagnosis of advanced pancreatic cancer.

Chemotherapy is usually the first treatment you get for advanced pancreatic cancer. If it doesn't work, the traditional second-line treatment has long been more chemo with a different mix of drugs (plus other treatments, sometimes). The main treatments that oncologists have to choose from are gemcitabine (alone or with another chemo drug), Folfirinox (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin), and Nalirifox (liposomal irinotecan, 5-fluorouracil/leucovorin, and oxaliplatin). But second-line treatment options may soon expand beyond chemo in an exciting way.

In August 2026, the FDA approved a targeted drug called daraxonrasib as a potentially powerful second-line option. Daraxonrasib is "one of the biggest advances that we've had in pancreatic cancer ever," says Eric Christenson, MD, an oncologist at Johns Hopkins Medicine. Among people with stage IV of the most common type of pancreatic cancer (pancreatic adenocarcinoma), those who got daraxonrasib in a clinical trial lived for a median of 13.2 months, while those who got chemo lived 6.7 months, according to the drugmaker.

Targeted drugs like daraxonrasib attack gene changes (mutations), substances, or other features of pancreatic cancer cells that fuel their growth. Daraxonrasib is a pill that targets RAS mutations, which are found in more than 90% of people with pancreatic adenocarcinoma. Other targeted drugs for pancreatic cancer tackle various mutations. For example, olaparib (Lynparza) is an approved maintenance drug given after first-line chemo to some people with BRCA mutations. Research suggests that people with pancreatic cancer who get a personalized treatment that matches their cancer's biology live longer.

To find out if your cancer might respond to a targeted drug or another type of personalized medicine (such as immunotherapy), think about getting two types of tests ASAP. Biomarker testing involves getting a biopsy of your pancreatic cancer tumor. A lab then checks it for mutations, protein changes, or other biological features. With genetic testing, a lab checks a blood or saliva sample for mutations in your DNA that were passed down in your family or happened on their own. The results from these tests may help your doctor offer treatment options tailored to you.

Clinical trials are studies that can give you the chance to try promising treatments. With advanced pancreatic cancer, you can ask your doctor right away if there's a clinical trial that might be right for you. "A lot of these drugs coming through trials are extremely exciting," Christenson says. And "there's a significant reason to hope that using them earlier on will really maximize their benefit." You can ask if you're eligible for any trials at nearby centers to avoid the time commitment of traveling farther, says Wungki Park, MD, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center.

This treatment involves wearing a portable device that gives off low-energy electrical fields near your tumor. The energy makes the cancer cells less able to multiply. The use of tumor-treating fields as a second-line treatment along with chemotherapy has shown promise at boosting overall survival and improving pain control, typically for people with locally advanced pancreatic cancer, Christenson says. That's when cancer has grown too far into nearby blood vessels or other tissues to be removed completely with surgery, but hasn't spread to distant body parts. The value of tumor-treating fields for widespread (metastatic) pancreatic cancer isn't as well-researched, Christenson says.

In cancer centers around the world, researchers are putting artificial intelligence tools to the test – sometimes with hopeful results. Certain AI tools have shown early promise in helping health care professionals spot advanced pancreatic cancer earlier, choose chemo treatment for it, and discover combinations of drugs that work better together. Widespread use of effective AI tools that help diagnose and treat advanced pancreatic cancer may still be years away. But artificial intelligence has at least one practical use right now: It may help your oncologist match you with a clinical trial sooner.

If you're thinking about getting a second-line treatment, have a talk with your oncologist about your goals for treatment. Ask about the possible benefits and risks of any medication or test you're considering. Also ask your doctor to connect you with a palliative or supportive care team early on for help managing cancer symptoms and medication side effects, Park says. With any treatment, understanding what to expect and having that discussion with your oncologist so that everyone's on the same page is key, he says.